Eli Lilly: raises FY EPS targets
(CercleFinance.com) - On unveiling better-than-expected quarterly releases, Eli Lilly says that it now expects FY 2019 adjusted EPS of 5.
67 dollars to 5.77 dollars, up from a previous target range of 5.60 dollars to 5.70 dollars.
In Q2, the group posted adjusted EPS that is up 1% at 1.50 dollar, five cents above the consensus, for revenues that are up 1% at 5.64 billion dollars, with volumes up 6%, albeit offset somewhat by price and FX factors.
"Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Basaglar, Emgality and Cyramza, contributed 13 percentage points of revenue growth and represented approximately 43 percent of total revenue," the pharmaceutical group said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
67 dollars to 5.77 dollars, up from a previous target range of 5.60 dollars to 5.70 dollars.
In Q2, the group posted adjusted EPS that is up 1% at 1.50 dollar, five cents above the consensus, for revenues that are up 1% at 5.64 billion dollars, with volumes up 6%, albeit offset somewhat by price and FX factors.
"Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Basaglar, Emgality and Cyramza, contributed 13 percentage points of revenue growth and represented approximately 43 percent of total revenue," the pharmaceutical group said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.